Vicki Sato, Ph.D. has served as a member of our Board since July 2021. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. Previously, she served as President of Vertex Pharmaceuticals, Inc. ("Vertex"), a publicly traded biotechnology company, which she joined in 1992. Prior to becoming President of Vertex, she was the Chief Scientific Officer and Senior Vice President of Research and Development. Prior to joining Vertex, Dr. Sato served as Vice President of Research at Biogen Inc. Dr. Sato currently serves on the board of directors of Vir Biotechnology, Inc., a publicly traded company. She also serves on the boards of Encoded Therapeutics, Inc. and Aera Therapeutics, Inc., each a private biotechnology company, and is a venture partner at ClavysBio Pte Ltd and ARCH Venture Partners. Dr. Sato previously served on the boards of directors of Denali Therapeutics, Inc. (2015-2025), Bristol-Myers Squibb Company (2006-2021), BorgWarner Inc. (2014-2021), and Akouos, Inc. (2020-2022). Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.